This product is for research use only, not for human use. We do not sell to patients.
| Size | Price | Stock |
|---|---|---|
| 25mg | $65 | 3-6 Days |
| 50mg | $95 | 3-6 Days |
| 100mg | $140 | 3-6 Days |
| 250mg | $200 | 3-6 Days |
| 500mg | $330 | 3-6 Days |
| 1g | $490 | 3-6 Days |
: Cat #: V1964 CAS #: 79455-30-4 Purity ≥ 98%
Description: Nicaraven is a hydroxyl radical scavenger with antivasospastic and neuroprotective effects. Nicaraven causes a dose-dependent, slight inhibition of poly (ADP-ribose) synthetase activation, possibly due to a direct inhibitory effect on the catalytic activity of poly (ADP-ribose) synthetase in RAW murine macrophages stimulated with peroxynitrite. Nicaraven partially protects against the peroxynitrite-induced suppression of mitochondrial respiration in RAW macrophages and causes a slight, dose-dependent inhibition of nitrite production in RAW macrophages stimulated with bacterial lipopolysaccharide.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
| Molecular Weight (MW) | 284.31 |
|---|---|
| Molecular Formula | C15H16N4O2 |
| CAS No. | 79455-30-4 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility In Vitro | DMSO: 57 mg/mL (200.5 mM) |
| Water: 57 mg/mL (200.5 mM) | |
| Ethanol: 57 mg/mL (200.5 mM) | |
| Synonyms | N,N'-(propane-1,2-diyl)dinicotinamide |
| Protocol | In Vitro | In vitro activity: Nicaraven causes a dose-dependent, slight inhibition of poly (ADP-ribose) synthetase activation, possibly due to a direct inhibitory effect on the catalytic activity of poly (ADP-ribose) synthetase in RAW murine macrophages stimulated with peroxynitrite. Nicaraven partially protects against the peroxynitrite-induced suppression of mitochondrial respiration in RAW macrophages and causes a slight, dose-dependent inhibition of nitrite production in RAW macrophages stimulated with bacterial lipopolysaccharide. Nicaraven (0.35 mM) significantly inhibits the maximum aggregation rate induced by adenosine diphosphate (ADP) in the healthy volunteer platelets. Nicaraven (1.75 mM) significantly reduces the maximum aggregation rate induced by collagen in platelets. Nicaraven induces dose-dependent inhibition of platelet aggregation in both healthy volunteers and patients with cerebral thrombosis. |
|---|---|---|
| In Vivo | Nicaraven inhibits lipid peroxidation in the liver of beagle dogs, improves hepatic and systemic hemodynamics and energy metabolism, and suppresses liver enzyme release, endothelin-1 elevation in hepatic venous blood, histologic damage, and neutrophil infiltration into the liver. Nicaraven (20 mg/kg) elicits small reductions in infarction volume in male Sprague-Dawley rats subjected to transient focal ischemia. Nicaraven (60 mg/kg) provides significant reductions in the volume of infarction (18.6% and 20.9%) reductions for the pre- and posttreatment groups, respectively, in male Sprague-Dawley rats subjected to transient focal ischemia. |
| Solvent volume to be added | Mass (the weight of a compound) | |||
|---|---|---|---|---|
| Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
| 1mM | 3.5173 mL | 17.5864 mL | 35.1729 mL | 70.3457 mL |
| 5mM | 0.7035 mL | 3.5173 mL | 7.0346 mL | 14.0691 mL |
| 10mM | 0.3517 mL | 1.7586 mL | 3.5173 mL | 7.0346 mL |
| 20mM | 0.1759 mL | 0.8793 mL | 1.7586 mL | 3.5173 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.